CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD

Clinical Nutrition

Volumn 25, Issue 3, 2006, Pages 454-465

  Bassaganya Riera, Josep ^a,b   Hontecillas, Raquel ^a,b  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b IOWA STATE UNIVERSITY   (United States)

Author keywords

CLA; Immunomodulators; Intestinal health; n 3 PUFA; Pig models

Indexed keywords

ALPHA TOCOPHEROL; C 38; CALCIUM CARBONATE; CALCIUM PHOSPHATE DIBASIC; CLARINOL; COLECALCIFEROL; CONJUGATED LINOLEIC ACID; CYANOCOBALAMIN; DEXTRAN SULFATE; DOCOSAHEXAENOIC ACID; DRONABINOL; FISH OIL; G 80; ICOSAPENTAENOIC ACID; IRON; KERATINOCYTE GROWTH FACTOR; LINOLEIC ACID; NICOTINIC ACID; OMEGA 3 FATTY ACID; PANTOTHENIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RETINOL ACETATE; RIBOFLAVIN; SELENIUM; SODIUM CHLORIDE; SOYBEAN OIL; TRACE ELEMENT; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 3; UNINDEXED DRUG; VACCENIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET SUPPLEMENTATION; DISEASE SEVERITY; DOWN REGULATION; DRUG POTENTIATION; ENTERITIS; ENZYME ACTIVATION; ENZYME INDUCTION; EXPERIMENTAL MODEL; FOOD COMPOSITION; GENE EXPRESSION; GROWTH INHIBITION; IMMUNOMODULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; QUANTITATIVE ANALYSIS; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SWINE; TISSUE REGENERATION; UPREGULATION;

ANIMALS; COLON; DEXTRAN SULFATE; DIET; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; EATING; FATTY ACIDS, OMEGA-3; GENE EXPRESSION; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; LINOLEIC ACIDS, CONJUGATED; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR DELTA; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SWINE; UP-REGULATION; WEIGHT GAIN;

EID: 33744937585     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2005.12.008     Document Type: Article

References (42)

1. Loftus Jr. E.V., and Sandborn W.J. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 31 (2002) 1-20
2. Podolsky D.K. Mucosal immunity and inflammation. V. Innate mechanisms of mucosal defense and repair: the best offense is a good defense. Am J Physiol 277 (1999) G495-G499
3. Strober W., Fuss I.J., and Blumberg R.S. The immunology of mucosal models of inflammation. Annu Rev Immunol 20 (2002) 495-549
4. Camuesco D., Galvez J., Nieto A., et al. Dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, attenuates colonic inflammation in rats with DSS-induced colitis. J Nutr 135 (2005) 687-694
5. Andoh A., Tsujikawa T., Ishizuka I., et al. n-3 fatty acid-rich diet prevents early response of interleukin-6 elevation in trinitrobenzene sulfonic acid-induced enteritis. Int J Mol Med 12 (2003) 721-725
6. Nieto N., Torres M.I., Rios A., and Gil A. Dietary polyunsaturated fatty acids improve histological and biochemical alterations in rats with experimental ulcerative colitis. J Nutr 132 (2002) 11-19
7. Bassaganya-Riera J., King J., and Hontecillas R. Health benefits of conjugated linoleic acid: lessons from pig models in biomedical research. Eur J Lipid Sci Technol 106 (2004) 856-861
8. Bassaganya-Riera J., Hontecillas R., and Beitz D.C. Colonic anti-inflammatory mechanisms of conjugated linoleic acid. Clin Nutr 21 (2002) 451-459
9. Hontecillas R., Wannemeulher M.J., Zimmerman D.R., et al. Nutritional regulation of porcine bacterial-induced colitis by conjugated linoleic acid. J Nutr 132 (2002) 2019-2027
10. Bassaganya-Riera J., Reynolds K., Martino-Catt S., et al. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 127 (2004) 777-791
11. Kelley D.S., Taylor P.C., Nelson G.J., et al. Docosahexaenoic acid ingestion inhibits natural killer cell activity and production of inflammatory mediators in young healthy men. Lipids 34 (1999) 317-324
12. Kew S., Gibbons E.S., Thies F., McNeill G.P., Quinlan P.T., and Calder P.C. The effect of feeding structured triacylglycerols enriched in eicosapentaenoic or docosahexaenoic acids on murine splenocyte fatty acid composition and leucocyte phagocytosis. Br J Nutr 90 (2003) 1071-1080
13. Serhan C.N., Clish C.B., Brannon J., Colgan S.P., Chiang N., and Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192 (2000) 1197-1204
14. Albers R., Van Der Wielen R.P., Brink E.J., Hendriks H.F., Dorovska-Taran V.N., and Mohede I.C. Effects of cis-9, trans-11 and trans-10, cis-12 conjugated linoleic acid (CLA) isomers on immune function in healthy men. Eur J Clin Nutr 57 (2003) 595-603
15. Michalik L., Desvergne B., Tan N.S., et al. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol 154 (2001) 799-814
16. National Research Council. Nutrient requirements of swine (1998), National Academy Press, Washington, DC
17. Bassaganya-Riera J., Pogranichniy R.M., Jobgen S.C., et al. Conjugated linoleic acid ameliorates viral infectivity in a pig model of virally induced immunosuppression. J Nutr 133 (2003) 3204-3214
18. SAS. SAS/STAT user's guide (version 9.1.3). Cary, NC: SAS Institute Inc.; 2002.
19. Stenson W.F. Interleukin-4 hyporesponsiveness in inflammatory bowel disease: immune defect or physiological response?. Gastroenterology 108 (1995) 284-286
20. Cohen R.D., Larson L.R., Roth J.M., Becker R.V., and Mummert L.L. The cost of hospitalization in Crohn's disease. Am J Gastroenterol 95 (2000) 524-530
21. Barba G., Rebouissoux L., Le Bail B., and Lamireau T. Recurrent pancreatitis revealing Crohn's disease. Arch Pediatr 9 (2002) 1053-1055
22. Braverman I.M. Skin signs of gastrointestinal disease. Gastroenterology 124 (2003) 1595-1614
23. Lichtenstein GR, Abreu M, Present D. Recent advances in the treatment of Crohn's colitis. The Center for Health Care Education, LLC, 2003.
24. Marri S.R., and Buchman A.L. The education and employment status of patients with inflammatory bowel diseases. Inflamm Bowel Dis 11 (2005) 171-177
25. Camilleri M. GI clinical research 2002-2003: the year in review. Clin Gastroenterol Hepatol 1 (2003) 415-420
26. MacLean C.H., Mojica W.A., Newberry S.J., et al. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease. Am J Clin Nutr 82 (2005) 611-619
27. Yang M., and Cook M.E. Dietary conjugated linoleic acid decreased cachexia, macrophage tumor necrosis factor-alpha production, and modifies splenocyte cytokines production. Exp Biol Med (Maywood) 228 (2003) 51-58
28. Mokdad A.H., Bowman B.A., Ford E.S., Vinicor F., Marks J.S., and Koplan J.P. The continuing epidemics of obesity and diabetes in the United States. JAMA 286 (2001) 1195-1200
29. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20 (1999) 649-688
30. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108 (2003) 2941-2948
31. Katayama K., Wada K., Nakajima A., et al. A novel PPARgamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 124 (2003) 1315-1324
32. Dubuquoy L., Jansson E.E., Deeb S., et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 124 (2003) 1265-1276
33. Mangelsdorf D.J., Thummel C., Beato M., et al. The nuclear receptor superfamily: the second decade. Cell 83 (1995) 835-839
34. Su C.G., Wen X., Bailey S.T., et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104 (1999) 383-389
35. Desreumaux P., Dubuquoy L., Nutten S., et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 193 (2001) 827-838
36. Kelly D., Campbell J.I., King T.P., et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 5 (2004) 104-112
37. Lee J.Y., and Hwang D.H. Docosahexaenoic acid suppresses the activity of peroxisome proliferator-activated receptors in a colon tumor cell line. Biochem Biophys Res Commun 298 (2002) 667-674
38. Ido A., Numata M., Kodama M., and Tsubouchi H. Mucosal repair and growth factors: recombinant human hepatocyte growth factor as an innovative therapy for inflammatory bowel disease. J Gastroenterol 40 (2005) 925-931
39. Chen Y., Chou K., Fuchs E., Havran W.L., and Boismenu R. Protection of the intestinal mucosa by intraepithelial gamma delta T cells. Proc Natl Acad Sci USA 99 (2002) 14338-14343
40. Hontecillas R., Bassaganya-Riera J., Wilson J., Hutto D.L., and Wannemuehler M.J. CD4+ T-cell responses and distribution at the colonic mucosa during Brachyspira hyodysenteriae-induced colitis in pigs. Immunology 115 (2005) 127-135
41. Lundqvist C., Baranov V., Soderstrom K., et al. Phenotype and cytokine profile of intraepithelial lymphocytes in human small and large intestine. Ann NY Acad Sci 756 (1995) 395-399
42. Lundqvist C., Hammarstrom S., and Hammarstrom M.L. Intraepithelial lymphocytes expressing TCR gamma delta in human gingival tissues. Adv Exp Med Biol 371B (1995) 1097-1102